pubmed.ncbi.nlm.nih.gov

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs - PubMed

Comparative Study

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

D Funch et al. Diabetes Obes Metab. 2014 Mar.

Abstract

Aim: We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme.

Methods: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates (IR/100 000 person-years), rate ratio (RR) and 95% confidence intervals (CI) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models.

Results: The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non-glucagon-like peptide-1 (GLP-1)-based therapies (adjusted RR 1.10; CI 0.81-1.49). The IR for pancreatic cancer was 19.9 for liraglutide compared with 33.0 for all non-GLP-1-based therapies (adjusted RR 0.65; 95% CI 0.26-1.60).

Conclusion: We did not observe excess risk of either outcome associated with liraglutide relative to individual or pooled comparator drugs.

Keywords: GLP-1; observational study; pharmaco-epidemiology.

PubMed Disclaimer

Cited by

Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study.
Chang CH, Lin JW, Chen ST, Lai MS, Chuang LM, Chang YC. Chang CH, et al. Medicine (Baltimore). 2016 Feb;95(7):e2603. doi: 10.1097/MD.0000000000002603. Medicine (Baltimore). 2016. PMID: 26886601 Free PMC article.
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.
Rigato M, Fadini GP. Rigato M, et al. Diabetes Metab Syndr Obes. 2014 Mar 18;7:107-20. doi: 10.2147/DMSO.S37644. eCollection 2014. Diabetes Metab Syndr Obes. 2014. PMID: 24672252 Free PMC article. Review.
Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop.
Moses AC, Knudsen LB, Svendsen CB. Moses AC, et al. Pancreas. 2014 May;43(4):657. doi: 10.1097/MPA.0000000000000037. Pancreas. 2014. PMID: 24713674 Free PMC article. No abstract available.
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies Investigators. Azoulay L, et al. BMJ. 2016 Feb 17;352:i581. doi: 10.1136/bmj.i581. BMJ. 2016. PMID: 26888382 Free PMC article.
Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study.
Lin HD, Lai CL, Dong YH, Tu YK, Chan KA, Suissa S. Lin HD, et al. Drugs Real World Outcomes. 2019 Sep;6(3):93-104. doi: 10.1007/s40801-019-0156-2. Drugs Real World Outcomes. 2019. PMID: 31240630 Free PMC article.

References

1. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study. JAMA Intern Med. 2013;173:534–539. - PubMed
1. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011 Jul;141:150–156. - PMC - PubMed
1. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36:2118–2125. - PMC - PubMed
1. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011 Jun;13:559–566. - PubMed
1. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther. 2012 Oct;14:904–911. - PMC - PubMed

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs - PubMed